1042 GMT - GSK's first-quarter results could be modestly negative, with U.S. prescriptions trends pointing to a weak performance at the U.K. drugmaker's general medicines segment, UBS analysts say in a research note. HIV treatment Cabenuva, lupus drug Benlysta and respiratory medicine Nucala are likely to deliver continued positive top-line momentum, UBS says. On the other hand, UBS estimates general medicines sales will be 4% below the consensus forecast. "We question whether an increase in patient out-of-pocket burden--copay or coinsurance--early in the year for respiratory products may have resulted in a higher level of prescription abandonment," the analysts say. Updates on the early uptake of recently launched drugs Blenrep and Exdensur as well as the HIV strategy will be in focus, UBS says. Shares rise 1.1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 06:43 ET (10:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.